CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

Core Viewpoint - CytoMed Therapeutics Limited has entered into an At-the-Market Sales Agreement to raise up to $4,304,945 through the sale of ordinary shares, which will be used for general corporate purposes and potential acquisitions [1][2][3] Group 1: Company Overview - CytoMed Therapeutics Limited is a clinical stage biopharmaceutical company based in Singapore, focused on developing novel donor blood-derived, cell-based allogeneic therapies for treating blood and solid cancers [1][4] - The company was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR) [4] - CytoMed utilizes proprietary technologies, including gamma delta T cells and iPSC-derived gamma delta Natural Killer T cells, to create immunotherapies inspired by the success of CAR-T therapies [4] Group 2: Financial Activities - The company has entered into a Sales Agreement with R.F. Lafferty & Co., Inc. to sell shares at its discretion based on market conditions and capital requirements [2] - Proceeds from the ATM program will be allocated for general corporate purposes, including business diversification, development initiatives, and capital expenditures [3] - The company has seen approximately 2,500 new customer sign-ups for its newly acquired cord blood bank since August 2024, contributing to revenue in 2025 [3]